Hadean Ventures

CardioMech is a Norwegian company focused on developing therapeutic devices for structural heart disease, specifically aimed at providing a transcatheter alternative to traditional cardiac surgery. Founded in 2015 and headquartered in Trondheim, the company specializes in catheter-based technology that facilitates the placement of artificial chords for the mitral valve. This innovative approach allows surgeons to address severe symptomatic degenerative mitral regurgitation (DMR) caused by conditions such as prolapse or flail, without the need for open-heart surgery. By enabling minimally invasive procedures, CardioMech's devices offer new therapeutic options for patients suffering from moderate to severe mitral regurgitation, thereby improving treatment outcomes while reducing the risks associated with more invasive surgical methods.